Role of Pharmacists in the Management of Dyslipidaemia
Dyslipidaemia is a modifiable yet highly prevalent risk factor for atherosclerotic disease and its complications, including coronary heart disease (CHD), myocardial infarction (MI), stroke, peripheral vascular disease and cardiac death.
The management of dyslipidaemia primarily focuses on controlling elevated LDL-C levels based on guideline recommendations, along with a secondary focus on correcting other lipid levels such as non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C and triglycerides (TGs).
Thank you for visiting the AstraZeneca Medicines website
This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.
Do you wish to continue?
Thank you for visiting the AstraZeneca Medicines website
This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.